Citation sources

Updated weekly. Details via Crossref
Crossref Scopus Google Scholar
39 39 Search
2025
Impregnation of mesenchymal stem cell conditioned media with wortmannin enhanced its antiproliferative effect in breast cancer cells via PI3K/Akt/mTOR pathway
BMC Research Notes
2025
Novel Estrogen Receptor – Targeted Therapies in Hormone-Receptor Positive Breast Cancer
Current Treatment Options in Oncology
2025
Predicting immune responsiveness in ER-positive breast cancer for personalized therapy: a population-based study
npj Precision Oncology
2024
A Multiplex Assay for Fast PIK3CA Hotspot Mutation Characterization in a Single Specimen by 3-Color Digital PCR Analysis
The Journal of Applied Laboratory Medicine
2024
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
npj Breast Cancer
2024
GRK2 Protein Mediates the ANRIL, a lncRNA, to Affect the Proliferation and Apoptosis of Kasumi-1 Cells
Frontiers in Bioscience-Landmark
2024
Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
Journal of Translational Medicine
2023
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges
Biomedicines
2023
MAGI1 Prevents Senescence and Promotes the DNA Damage Response in ER+ Breast Cancer
Cells
2023
The Evolution of Affordable Technologies in Liquid Biopsy Diagnostics: The Key to Clinical Implementation
Cancers
2023
A comparative study of Bazedoxifene, Exemestane, Fulvestrant, Raloxifene, Tryprostatin A, and Vorinostat compounds as potential inhibitors against breast cancer through molecular docking, and molecular dynamics simulation
Chinese Journal of Analytical Chemistry
2022
A multidisciplinary approach to optimizing care of patients treated with alpelisib
The Breast
2022
Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein
Biomedicines
2022
13-Acetoxysarcocrassolide induces apoptosis in human hepatocellular carcinoma cells through mitochondrial dysfunction and suppression of the PI3K/AKT/mTOR/p70S6K signalling pathway
Pharmaceutical Biology
2022
PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
Cells
2022
Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia
Integrative Cancer Therapies
2021
Harmine Hydrochloride Mediates the Induction of G2/M Cell Cycle Arrest in Breast Cancer Cells by Regulating the MAPKs and AKT/FOXO3a Signaling Pathways
Molecules
2021
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance
Critical Reviews in Oncology/Hematology
2021
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer
European Journal of Clinical Investigation
2021
A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy
Frontiers in Oncology
2021
The Long-Term DEHP Exposure Confers Multidrug Resistance of Triple-Negative Breast Cancer Cells through ABC Transporters and Intracellular ROS
Antioxidants
2021
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer
Clinical Cancer Research
2021
Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis—New insight and futuristic vision
International Journal of Biological Macromolecules
2021
Harmine Hydrochloride Triggers G2/M Cell Cycle Arrest and Apoptosis in HCT116 Cells through ERK and PI3K/AKT/mTOR Signaling Pathways
Preventive Nutrition and Food Science
2021
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
Journal of Modern Oncology
2020
Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer
Breast Cancer Research and Treatment
2020
Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups
Scientific Reports
2020
<p>Resistance and Overcoming Resistance in Breast Cancer</p>
Breast Cancer: Targets and Therapy
2020
Understanding Breast cancer: from conventional therapies to repurposed drugs
European Journal of Pharmaceutical Sciences
2020
In silico molecular docking studies and MM/GBSA analysis of coumarin-carbonodithioate hybrid derivatives divulge the anticancer potential against breast cancer
Beni-Suef University Journal of Basic and Applied Sciences
2020
Advances in Experimental Medicine and Biology
2020
Testing considerations for phosphatidylinositol‐3‐kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer
Cancer Medicine
2020
HS‑146, a novel phosphoinositide 3‑kinase α inhibitor, induces the apoptosis and inhibits the metastatic ability of human breast cancer cells
International Journal of Oncology
2019
Chemoproteomic Selectivity Profiling of PIKK and PI3K Kinase Inhibitors
ACS Chemical Biology
2019
PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(l‐Glutamic Acid)‐Combretastatin A4 Conjugate in Metastatic Breast Cancer
Advanced Science
2019
Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy
ACS Applied Materials & Interfaces
2019
The Role of PTEN in Innate and Adaptive Immunity
Cold Spring Harbor Perspectives in Medicine
2019
PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence
Current Drug Targets
Additional cited-by details will be shown when available from Crossref